Should We Be Giving Weight-Loss Drugs To Children?, Pg15

Key Highlights:

• A Phase III trial by Novo Nordisk showed semaglutide helped 40.4% of obese children (6-12 years) move below the obesity threshold.
• The STEP Young trial demonstrated a significant reduction in Body Mass Index (BMI) when semaglutide was combined with lifestyle changes.
• Childhood obesity is an escalating problem in India, contributing to early-onset Type 2 diabetes, hypertension, and liver disease.
• The drug offers substantial weight reduction, potentially altering long-term metabolic trajectories in severely obese children.

Detailed Insights:

• The trial involved children aged six to under 12 years, with over 85% having severe obesity (Class II or III) at the study's start.
• Semaglutide provided incremental benefits beyond lifestyle modifications, which included a reduced-calorie diet and increased physical activity.
• Pharmacological treatment in young children raises concerns about long-term safety, nutritional impact, and effects on growth and development.
• In India, the high cost and limited availability make such therapies largely inaccessible to the majority of families.
• There is a risk of medicalizing obesity without adequately addressing underlying family and environmental factors that drive it.
• Comprehensive management requires assessing metabolic health, improving physical activity, ensuring adequate protein and micronutrient intake, and reducing screen time.
• Parental modification of household eating and activity patterns alongside the child is crucial for sustained benefits.

Scientific/Technical Concepts Involved:

• Semaglutide: A GLP-1 receptor agonist drug used for managing Type 2 diabetes and chronic weight management.
• Body Mass Index (BMI): A measure calculated from a person's weight and height, used to screen for weight categories.
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A condition characterized by fat accumulation in the liver, not due to alcohol.
• Polycystic Ovarian Syndrome (PCOS): A hormonal disorder common among women of reproductive age, often linked to obesity and insulin resistance.